Trials / Completed
CompletedNCT04507230
COVID-19 Associated Coagulopathy in Egypt
Assessment of COVID-19 Associated Coagulopathy and Hypercoagulable State in Upper Egypt
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 106 (actual)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most commonly observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation (DIC) compared to 0.6% of survivors.
Detailed description
studying the detailed coagulation screen and second line coagulation parameters including both thrombophilia screen and other acute phase coagulation factors.
Conditions
Timeline
- Start date
- 2020-08-07
- Primary completion
- 2020-10-31
- Completion
- 2020-10-31
- First posted
- 2020-08-11
- Last updated
- 2021-03-11
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04507230. Inclusion in this directory is not an endorsement.